Author: admin

DelveInsight’s “Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Myelodysplastic Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myelodysplastic Syndrome Market Forecast

Some of the key facts of the Myelodysplastic Syndrome Market Report: 

• The Myelodysplastic Syndrome market size was valued approximately USD 1,924 million in 2020 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In January 2024, Faron Pharmaceuticals announced that the first patient has been dosed in Phase II of the BEXMAB trial that evaluates the safety and efficacy of bexmarilimab, in combination with standard of care (SoC) in patients with hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndrome (MDS). 

• In October 2023, Servier announced that the US Food and Drug Administration (FDA) has approved TIBSOVO (ivosidenib tablets) for the treatment of patients with isocitrate dehydrogenase 1 (IDH1)- mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS). 

• In August 2023, Bristol Myers Squibb announced that the US FDA has approved REBLOZYL (luspatercept-aamt) for the treatment of anemia without previous erythropoiesis stimulating agent use (ESAnaïve) in adult patients with very low- to intermediate-risk MDS who may require regular red blood cell (RBC) transfusions.

• According to DelveInsight, the collective incident population of MDS across the 7MM was approximately 42,000 in 2023. Projections suggest that these figures will rise by 2034.

• In the EU4 and the UK, Germany recorded the highest incident population of MDS, totaling around 4,500 cases, followed by France. Conversely, Spain reported the lowest incident population of MDS in 2023.

• In the United States, the predominant subtype of MDS cases was RAEB/MDS-EB, representing approximately 7,000 cases in 2023. Projections indicate an anticipated increase in these numbers by 2034.

• Key Myelodysplastic Syndrome Companies: University Hospital, Grenoble, Kind Pharmaceuticals LLC, Otsuka Beijing Research Institute, Agios Pharmaceuticals, Bristol-Myers Squibb, Syros Pharmaceuticals, H. Lee Moffitt Cancer Center, Novartis, Acceleron Pharma, Celgene, Eli Lilly and Company, Geron Corporation, Amgen, Astex Pharmaceuticals, Hoffmann-La Roche, Janssen Research & Development, and others

• Key Myelodysplastic Syndrome Therapies: Deferasirox, AND017, Decitabine, AG-946, Luspatercept, Tamibarotene, INCB024360, MBG453, ACE-536, Durvalumab, Galunisertib, Imetelstat, Darbepoetin Alfa, ASTX727 LD, Epoetin beta, Talacotuzumab, and others

• The Myelodysplastic Syndrome epidemiology based on gender analyzed that Myelodysplastic Syndrome is more common in men as compared to women

• The Myelodysplastic Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myelodysplastic Syndrome pipeline products will significantly revolutionize the Myelodysplastic Syndrome market dynamics.

Myelodysplastic Syndrome Overview

Myelodysplastic syndromes (MDS) are a group of disorders characterized by abnormal development and function of blood cells in the bone marrow. In MDS, the bone marrow fails to produce enough healthy blood cells, including red blood cells, white blood cells, and platelets. This results in cytopenias (low blood cell counts) and can lead to symptoms such as fatigue, weakness, shortness of breath, frequent infections, and easy bruising or bleeding.

Get a Free sample for the Myelodysplastic Syndrome Market Report:

https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market

Myelodysplastic Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Myelodysplastic Syndrome Epidemiology Segmentation:

The Myelodysplastic Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Myelodysplastic Syndrome

• Prevalent Cases of Myelodysplastic Syndrome by severity

• Gender-specific Prevalence of Myelodysplastic Syndrome

• Diagnosed Cases of Episodic and Chronic Myelodysplastic Syndrome

Download the report to understand which factors are driving Myelodysplastic Syndrome epidemiology trends @ Myelodysplastic Syndrome Epidemiology Forecast

Myelodysplastic Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myelodysplastic Syndrome market or expected to get launched during the study period. The analysis covers Myelodysplastic Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Myelodysplastic Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Myelodysplastic Syndrome Therapies and Key Companies

• Deferasirox: University Hospital, Grenoble

• AND017: Kind Pharmaceuticals LLC

• Decitabine: Otsuka Beijing Research Institute

• AG-946: Agios Pharmaceuticals

• Luspatercept: Bristol-Myers Squibb

• Tamibarotene: Syros Pharmaceuticals

• Luspatercept: Bristol-Myers Squibb

• INCB024360: H. Lee Moffitt Cancer Center

• MBG453: Novartis

• ACE-536: Acceleron Pharma

• Durvalumab: Celgene

• Galunisertib: Eli Lilly and Company

• Imetelstat: Geron Corporation

• Darbepoetin Alfa: Amgen

• ASTX727 LD: Astex Pharmaceuticals

• Epoetin beta: Hoffmann-La Roche

• Talacotuzumab: Janssen Research & Development

Discover more about therapies set to grab major Myelodysplastic Syndrome market share @ Myelodysplastic Syndrome Treatment Market

Myelodysplastic Syndrome Market Strengths

• The current treatment options for MDS include curative, supportive, and symptomatic treatments that are easily and widely available in the market, along with their generics.

Myelodysplastic Syndrome Market Opportunities

• Various studies have highlighted the role of multiple gene mutations like RUNX1, TP53, TET2, DNMT3A, ASXL1, and others in MDS. Developing therapies with targetable mutations will open a new window of opportunity for companies developing therapies for MDS.

Scope of the Myelodysplastic Syndrome Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Myelodysplastic Syndrome Companies: University Hospital, Grenoble, Kind Pharmaceuticals LLC, Otsuka Beijing Research Institute, Agios Pharmaceuticals, Bristol-Myers Squibb, Syros Pharmaceuticals, H. Lee Moffitt Cancer Center, Novartis, Acceleron Pharma, Celgene, Eli Lilly and Company, Geron Corporation, Amgen, Astex Pharmaceuticals, Hoffmann-La Roche, Janssen Research & Development, and others

• Key Myelodysplastic Syndrome Therapies: Deferasirox, AND017, Decitabine, AG-946, Luspatercept, Tamibarotene, INCB024360, MBG453, ACE-536, Durvalumab, Galunisertib, Imetelstat, Darbepoetin Alfa, ASTX727 LD, Epoetin beta, Talacotuzumab, and others

• Myelodysplastic Syndrome Therapeutic Assessment: Myelodysplastic Syndrome current marketed and Myelodysplastic Syndrome emerging therapies

• Myelodysplastic Syndrome Market Dynamics: Myelodysplastic Syndrome market drivers and Myelodysplastic Syndrome market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Myelodysplastic Syndrome Unmet Needs, KOL’s views, Analyst’s views, Myelodysplastic Syndrome Market Access and Reimbursement 

To know more about Myelodysplastic Syndrome companies working in the treatment market, visit @ Myelodysplastic Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Myelodysplastic Syndrome Market Report Introduction

2. Executive Summary for Myelodysplastic Syndrome

3. SWOT analysis of Myelodysplastic Syndrome

4. Myelodysplastic Syndrome Patient Share (%) Overview at a Glance

5. Myelodysplastic Syndrome Market Overview at a Glance

6. Myelodysplastic Syndrome Disease Background and Overview

7. Myelodysplastic Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Myelodysplastic Syndrome 

9. Myelodysplastic Syndrome Current Treatment and Medical Practices

10. Myelodysplastic Syndrome Unmet Needs

11. Myelodysplastic Syndrome Emerging Therapies

12. Myelodysplastic Syndrome Market Outlook

13. Country-Wise Myelodysplastic Syndrome Market Analysis (2020–2034)

14. Myelodysplastic Syndrome Market Access and Reimbursement of Therapies

15. Myelodysplastic Syndrome Market Drivers

16. Myelodysplastic Syndrome Market Barriers

17.  Myelodysplastic Syndrome Appendix

18. Myelodysplastic Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myelodysplastic Syndrome Market to Exhibit Rapid Growth Rate During the Forecast Period (2024-2034), Investigates DelveInsight | Fibrogen, Abbvie, Gilead Sciences, Novartis, Syros Pharmaceuticals

DelveInsight’s “Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Sickle Cell Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sickle Cell Disease Market Forecast

Some of the key facts of the Sickle Cell Disease Market Report: 

• The Sickle Cell Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In May 2023, The experimental cell-based gene-editing therapy called EDIT-301, administered as a single infusion, received orphan drug designation from the US Food and Drug Administration (FDA) for treating sickle cell disease (SCD).

• In April 2023, bluebird bio, Inc. has announced the submission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the gene therapy lovotibeglogene autotemcel (lovo-cel) aimed at patients aged 12 and above with sickle cell disease (SCD) who have a history of vaso-occlusive events (VOEs). The BLA includes a request for Priority Review, seeking to shorten the FDA’s review process to six months from the filing date, compared to the standard review duration of 10 months. If approved, lovo-cel will mark bluebird bio’s third ex-vivo gene therapy endorsed by the FDA for a rare genetic disorder and its second FDA approval targeting an inherited hemoglobin disorder. This advancement builds upon the company’s decade-long leadership in the field of gene therapy.

• Oxbryta, developed by Global Blood Therapeutics, is a medication that inhibits the polymerization of hemoglobin S. It is intended for treating sickle cell disease (SCD) in both adults and pediatric patients aged 12 years and above. Its approval was granted under accelerated approval based on its capacity to raise hemoglobin (Hb) levels. The drug is recommended for oral administration.

• New gene therapy options are in development for sickle cell disease treatment, such as CTX001 by CRISPR Therapeutics and Vertex Pharmaceuticals, and LentiGlobin BB305/Betibeglogene autotemcel by Bluebird Bio..

• Key Sickle Cell Disease Companies: Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others 

• Key Sickle Cell Disease Therapies: Inclacumab, GMI-1687, BIVV003, CSL889, Siplizumab, Etavopivat Tablets, VIT-2763, Crizanlizumab, Epeleuton, Voxelotor, Hydroxycarbamide, Exagamglogene autotemcel, Mitapivat, Canakinumab, ALXN1820, Crovalimab, EDIT 301, BIVV003, BEAM101, Hemopexin, and others

• The Sickle Cell Disease epidemiology based on gender analyzed that Sickle Cell Disease affects males and females equally

• The Sickle Cell Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sickle Cell Disease pipeline products will significantly revolutionize the Sickle Cell Disease market dynamics.

Sickle Cell Disease Overview

Sickle cell disease (SCD) is a genetic blood disorder characterized by abnormal hemoglobin, the protein in red blood cells that carries oxygen throughout the body. In SCD, the hemoglobin forms abnormal crescent-shaped or “sickle” cells instead of the normal disc shape. These sickle cells are rigid and can stick to vessel walls, leading to blockages that hinder blood flow and cause pain, organ damage, and other complications.

Get a Free sample for the Sickle Cell Disease Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/sickle-cell-disease-market

Sickle Cell Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Sickle Cell Disease Epidemiology Segmentation:

The Sickle Cell Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Sickle Cell Disease

• Prevalent Cases of Sickle Cell Disease by severity

• Gender-specific Prevalence of Sickle Cell Disease

• Diagnosed Cases of Episodic and Chronic Sickle Cell Disease

Download the report to understand which factors are driving Sickle Cell Disease epidemiology trends @ Sickle Cell Disease Epidemiology Forecast

Sickle Cell Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sickle Cell Disease market or expected to get launched during the study period. The analysis covers Sickle Cell Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Sickle Cell Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Sickle Cell Disease Therapies and Key Companies

• Inclacumab: Pfizer

• GMI-1687: Glycomimetics

• BIVV003: Sanofi

• CSL889: CSL Behring

• Siplizumab: ITB-Med LLC

• Etavopivat Tablets: Novo Nordisk A/S

• VIT-2763: Fortrea, Inc.

• Crizanlizumab: Novartis

• Epeleuton: Afimmune

• Voxelotor: Pfizer

• Hydroxycarbamide: ADDMEDICA SASA

• Exagamglogene autotemcel: CRISPR Therapeutics/Vertex Pharmaceuticals

• Mitapivat: Agios Pharmaceuticals

• Canakinumab: Novartis

• ALXN1820: Alexion Pharmaceuticals

• Crovalimab: Chugai Pharmaceutical/Roche

• EDIT 301: Editas Medicine

• BIVV003: Sangamo Therapeutics

• BEAM101: Beam Therapeutics

• Hemopexin: CSL Behring

Discover more about therapies set to grab major Sickle Cell Disease market share @ Sickle Cell Disease Treatment Landscape

Scope of the Sickle Cell Disease Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Sickle Cell Disease Companies: Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others

• Key Sickle Cell Disease Therapies: Inclacumab, GMI-1687, BIVV003, CSL889, Siplizumab, Etavopivat Tablets, VIT-2763, Crizanlizumab, Epeleuton, Voxelotor, Hydroxycarbamide, Exagamglogene autotemcel, Mitapivat, Canakinumab, ALXN1820, Crovalimab, EDIT 301, BIVV003, BEAM101, Hemopexin, and others

• Sickle Cell Disease Therapeutic Assessment: Sickle Cell Disease current marketed and Sickle Cell Disease emerging therapies

• Sickle Cell Disease Market Dynamics: Sickle Cell Disease market drivers and Sickle Cell Disease market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Sickle Cell Disease Unmet Needs, KOL’s views, Analyst’s views, Sickle Cell Disease Market Access and Reimbursement 

To know more about Sickle Cell Disease companies working in the treatment market, visit @ Sickle Cell Disease Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Sickle Cell Disease Market Report Introduction

2. Executive Summary for Sickle Cell Disease

3. SWOT analysis of Sickle Cell Disease

4. Sickle Cell Disease Patient Share (%) Overview at a Glance

5. Sickle Cell Disease Market Overview at a Glance

6. Sickle Cell Disease Disease Background and Overview

7. Sickle Cell Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Sickle Cell Disease 

9. Sickle Cell Disease Current Treatment and Medical Practices

10. Sickle Cell Disease Unmet Needs

11. Sickle Cell Disease Emerging Therapies

12. Sickle Cell Disease Market Outlook

13. Country-Wise Sickle Cell Disease Market Analysis (2019–2032)

14. Sickle Cell Disease Market Access and Reimbursement of Therapies

15. Sickle Cell Disease Market Drivers

16. Sickle Cell Disease Market Barriers

17.  Sickle Cell Disease Appendix

18. Sickle Cell Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sickle Cell Disease Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Vertex Pharma, Agios Pharma, Alexion Pharma, Novartis, Afimmune, Pfizer, ADDMED

The Thrombocytopenia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Thrombocytopenia pipeline products will significantly revolutionize the Thrombocytopenia market dynamics.  

DelveInsight’s “Thrombocytopenia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Thrombocytopenia, historical and forecasted epidemiology as well as the Thrombocytopenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Thrombocytopenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thrombocytopenia Market Forecast

Some of the key facts of the Thrombocytopenia Market Report: 

• The Thrombocytopenia market size was valued approximately USD 4,600 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In 2022, the total number of thrombocytopenia cases in the 7MM was approximately 2,624,000, with expectations for an increase in the forecast period.

• Within the 7MM, the United States reported the highest number of cases, approximately 1,054,900, of Thrombocytopenia in 2022.

• Within the EU4 and the UK, Germany recorded the highest number of cases, approximately 454,500, followed by the UK with around 271,000 cases. Conversely, Italy reported the lowest number of cases, approximately 127,500, in 2022.

• In 2022, Japan represented roughly 12% of the total Thrombocytopenia cases in the 7MM. Approximately 319,900 cases of thrombocytopenia were reported in Japan during that year.

• In 2022, the collective cases of ITP in the 7MM were estimated to be around 184,500. The United States contributed to approximately 36% of the total ITP cases within the 7MM.

• Key Thrombocytopenia Companies: Novartis, GlaxoSmithKline, UCB Biopharma, Eisai Inc., Veralox Therapeutics, Jiangsu HengRui Medicine, SK Plasma, Qidong Gaitianli Medicines, Amgen, Oscotec Inc., Octapharma, Kyowa Kirin, China Pharmaceutical, Encysive Pharmaceuticals, Biotest, Karyopharm Therapeutics, Qilu Pharmaceutical, and others

• Key Thrombocytopenia Therapies: Eltrombopag (ELT), SB497115, UCB7665, Avatrombopag, VLX-1005, Herombopag, LIV-GAMMA SN Inj.10%, Huaiqihuang Granule, Romiplostim, SKI-O-703, NewGam, Romiplostim, BT595, Argatroban, Selinexor, QL0911, and others

• The Thrombocytopenia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Thrombocytopenia pipeline products will significantly revolutionize the Thrombocytopenia market dynamics.

Thrombocytopenia Overview

Thrombocytopenia is a medical condition characterized by a low platelet count in the blood. Platelets are blood cells that help in blood clotting, and a reduced number of platelets can lead to abnormal bleeding or bruising. Thrombocytopenia can occur due to various factors, including decreased production of platelets in the bone marrow, increased destruction of platelets in the bloodstream or spleen, or increased usage of platelets in clot formation.

Get a Free sample for the Thrombocytopenia Market Report:

https://www.delveinsight.com/report-store/thrombocytopenia-market

Thrombocytopenia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Thrombocytopenia Epidemiology Segmentation:

The Thrombocytopenia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Thrombocytopenia

• Prevalent Cases of Thrombocytopenia by severity

• Gender-specific Prevalence of Thrombocytopenia

• Diagnosed Cases of Episodic and Chronic Thrombocytopenia

Download the report to understand which factors are driving Thrombocytopenia epidemiology trends @ Thrombocytopenia Epidemiology Forecast

Thrombocytopenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Thrombocytopenia market or expected to get launched during the study period. The analysis covers Thrombocytopenia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Thrombocytopenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Thrombocytopenia Therapies and Key Companies

• Eltrombopag (ELT): Novartis

• SB497115: GlaxoSmithKline

• UCB7665: UCB Biopharma SRL

• Avatrombopag: Eisai Inc.

• VLX-1005: Veralox Therapeutics

• Herombopag: Jiangsu HengRui Medicine

• LIV-GAMMA SN Inj.10%: SK Plasma

• Huaiqihuang Granule: Qidong Gaitianli Medicines

• Romiplostim: Amgen

• SKI-O-703: Oscotec Inc.

• NewGam: Octapharma

• Romiplostim: Kyowa Kirin China Pharmaceutical

• BT595: Biotest

• Argatroban: Encysive Pharmaceuticals

• Selinexor: Karyopharm Therapeutics

• QL0911: Qilu Pharmaceutical

Discover more about therapies set to grab major Thrombocytopenia market share @ Thrombocytopenia Treatment Market

Thrombocytopenia Market Drivers

• Emerging therapies with novel mechanisms of action that are targeting the different patient groups of thrombocytopenia and with an improvement of drug delivery mechanisms to increase patient compliance 

• Rise in the prevalence of thrombocytopenia due to various risk factors such as rise in chemotherapy use, chronic liver disease, etc

Thrombocytopenia Market Barriers

• Identification of new drug targets will boost the entry of novel therapies into the market

• Currently, no cure is available for congenital thrombocytopenia 

• Novel therapies for the treatment of refractory patients

Scope of the Thrombocytopenia Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Thrombocytopenia Companies: Novartis, GlaxoSmithKline, UCB Biopharma, Eisai Inc., Veralox Therapeutics, Jiangsu HengRui Medicine, SK Plasma, Qidong Gaitianli Medicines, Amgen, Oscotec Inc., Octapharma, Kyowa Kirin China Pharmaceutical, Encysive Pharmaceuticals, Biotest, Karyopharm Therapeutics, Qilu Pharmaceutical, and others

• Key Thrombocytopenia Therapies: Eltrombopag (ELT), SB497115, UCB7665, Avatrombopag, VLX-1005, Herombopag, LIV-GAMMA SN Inj.10%, Huaiqihuang Granule, Romiplostim, SKI-O-703, NewGam, Romiplostim, BT595, Argatroban, Selinexor, QL0911, and others

• Thrombocytopenia Therapeutic Assessment: Thrombocytopenia current marketed and Thrombocytopenia emerging therapies

• Thrombocytopenia Market Dynamics: Thrombocytopenia market drivers and Thrombocytopenia market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Thrombocytopenia Unmet Needs, KOL’s views, Analyst’s views, Thrombocytopenia Market Access and Reimbursement 

To know more about Thrombocytopenia companies working in the treatment market, visit @ Thrombocytopenia Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Thrombocytopenia Market Report Introduction

2. Executive Summary for Thrombocytopenia

3. SWOT analysis of Thrombocytopenia

4. Thrombocytopenia Patient Share (%) Overview at a Glance

5. Thrombocytopenia Market Overview at a Glance

6. Thrombocytopenia Disease Background and Overview

7. Thrombocytopenia Epidemiology and Patient Population

8. Country-Specific Patient Population of Thrombocytopenia 

9. Thrombocytopenia Current Treatment and Medical Practices

10. Thrombocytopenia Unmet Needs

11. Thrombocytopenia Emerging Therapies

12. Thrombocytopenia Market Outlook

13. Country-Wise Thrombocytopenia Market Analysis (2019–2032)

14. Thrombocytopenia Market Access and Reimbursement of Therapies

15. Thrombocytopenia Market Drivers

16. Thrombocytopenia Market Barriers

17.  Thrombocytopenia Appendix

18. Thrombocytopenia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Thrombocytopenia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Amgen, Novartis, GlaxoSmithKline, UCB Biopharma, Eisai Inc.